Tarsus Pharmaceuticals Inc (NASDAQ: TARS) kicked off on Tuesday, down -6.02% from the previous trading day, before settling in for the closing price of $47.49. Over the past 52 weeks, TARS has traded in a range of $20.08-$57.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 172.29% over the past five years. While this was happening, its average annual earnings per share was recorded 46.82%. With a float of $35.81 million, this company’s outstanding shares have now reached $38.35 million.
Let’s look at the performance matrix of the company that is accounted for 323 employees. In terms of profitability, gross margin is 92.99%, operating margin of -65.9%, and the pretax margin is -63.16%.
Tarsus Pharmaceuticals Inc (TARS) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Tarsus Pharmaceuticals Inc is 13.92%, while institutional ownership is 94.69%. The most recent insider transaction that took place on Mar 24 ’25, was worth 300,000. In this transaction President/CEO and Board Chair of this company sold 6,000 shares at a rate of $50.00, taking the stock ownership to the 824,106 shares. Before that another transaction happened on Mar 24 ’25, when Company’s Officer proposed sale 6,000 for $50.00, making the entire transaction worth $300,000.
Tarsus Pharmaceuticals Inc (TARS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 46.82% per share during the next fiscal year.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Trading Performance Indicators
Take a look at Tarsus Pharmaceuticals Inc’s (TARS) current performance indicators. Last quarter, stock had a quick ratio of 4.39. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.15.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.10, a number that is poised to hit -0.77 in the next quarter and is forecasted to reach 1.24 in one year’s time.
Technical Analysis of Tarsus Pharmaceuticals Inc (TARS)
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) saw its 5-day average volume 0.68 million, a positive change from its year-to-date volume of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 26.35%. Additionally, its Average True Range was 3.32.
During the past 100 days, Tarsus Pharmaceuticals Inc’s (TARS) raw stochastic average was set at 25.01%, which indicates a significant increase from 14.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.83% in the past 14 days, which was higher than the 52.36% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $48.99, while its 200-day Moving Average is $40.58. Nevertheless, the first resistance level for the watch stands at $47.92 in the near term. At $51.21, the stock is likely to face the second major resistance level. The third major resistance level sits at $53.41. If the price goes on to break the first support level at $42.43, it is likely to go to the next support level at $40.22. The third support level lies at $36.93 if the price breaches the second support level.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) Key Stats
The company with the Market Capitalisation of 1.86 billion has total of 38,377K Shares Outstanding. Its annual sales at the moment are 182,950 K in contrast with the sum of -115,550 K annual income. Company’s last quarter sales were recorded 66,410 K and last quarter income was -23,110 K.
